MYGN

Myriad Genetics, Inc. NASDAQ

Healthcare ·Medical - Diagnostics & Research ·US · myriad.com

$4.94

Mkt Cap $461.9M

52w Low $3.76 24.4% of range 52w High $8.59

50d MA $4.77 200d MA $6.04

P/E (TTM) -1.2x

EV/EBITDA -1.6x

P/B 1.2x

Debt/Equity 0.6x

ROE -99.4%

P/FCF 318.8x

RSI (14) —

ATR (14) —

Beta 1.64

50d MA $4.77

200d MA $6.04

Avg Volume 1.7M

About

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Ge…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 23, 2026	AMC	-0.02	0.04	+300.0%	4.38	+27.2%	+1.1%	+9.1%	+11.0%	+5.3%	+14.4%	—
Nov 3, 2025	AMC	-0.01	-0.13	-1200.0%	8.18	-9.3%	-21.0%	-19.6%	-22.6%	-23.0%	-20.8%	—
Aug 5, 2025	AMC	-0.01	0.05	+600.0%	3.87	+34.1%	+46.5%	+57.6%	+63.3%	+59.9%	+55.8%	—
May 6, 2025	AMC	-0.05	-0.03	+40.0%	7.27	-21.6%	-41.3%	-44.6%	-46.5%	-41.5%	-43.5%	—
Feb 24, 2025	AMC	0.03	0.03	+0.0%	13.78	-25.1%	-14.8%	-16.1%	-19.7%	-22.1%	-24.6%	—
Nov 7, 2024	AMC	0.02	0.06	+215.8%	17.67	+3.6%	-1.5%	-2.0%	-8.5%	-10.7%	-11.3%	—
Aug 6, 2024	AMC	0.01	0.05	+509.1%	25.96	+10.0%	+2.6%	+6.6%	+7.7%	+7.7%	+8.6%	—
May 7, 2024	AMC	-0.11	-0.01	+90.9%	19.78	+18.6%	+21.1%	+27.7%	+28.8%	+26.0%	+28.2%	—
Feb 27, 2024	AMC	0.01	0.04	+214.5%	23.50	-1.1%	-8.0%	-10.9%	-5.6%	-6.5%	-5.4%	—
Nov 6, 2023	AMC	-0.08	-0.03	+62.5%	16.34	+4.8%	+8.7%	+9.5%	-0.3%	+0.7%	+0.9%	—
Aug 3, 2023	AMC	-0.10	-0.08	+20.0%	20.76	-6.1%	-7.0%	-15.8%	-17.8%	-18.4%	-19.6%	—
May 3, 2023	AMC	-0.19	-0.21	-10.5%	21.89	-12.5%	-3.7%	-11.9%	-16.3%	-17.8%	-18.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 24	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$4.38	$5.57	+27.2%	+1.1%	+9.1%	+11.0%	+5.3%	+14.4%
Feb 24	UBS	Maintains	Neutral → Neutral	—	$4.38	$5.57	+27.2%	+1.1%	+9.1%	+11.0%	+5.3%	+14.4%
Nov 11	Piper Sandler	Maintains	Overweight → Overweight	—	$6.48	$6.45	-0.5%	+3.1%	+0.9%	-2.0%	+3.5%	+2.8%
Nov 5	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$6.46	$6.42	-0.6%	+1.9%	-2.0%	-2.5%	+0.3%	+3.4%
Nov 4	TD Cowen	Maintains	Hold → Hold	—	$8.18	$7.42	-9.3%	-21.0%	-19.6%	-22.6%	-23.0%	-20.8%
Nov 4	UBS	Maintains	Neutral → Neutral	—	$8.18	$7.42	-9.3%	-21.0%	-19.6%	-22.6%	-23.0%	-20.8%
May 21	Scotiabank	Downgrade	Sector Outperform → Sector Perform	—	$4.45	$4.25	-4.5%	-8.5%	-11.7%	-12.1%	-6.7%	-2.7%
May 15	Piper Sandler	Maintains	Overweight → Overweight	—	$3.84	$3.88	+1.0%	+7.0%	+7.6%	+15.4%	+15.9%	+6.0%
May 8	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$4.27	$4.29	+0.5%	-5.6%	-8.9%	-0.5%	-3.7%	-10.1%
May 7	UBS	Maintains	Neutral → Neutral	—	$7.27	$5.70	-21.6%	-41.3%	-44.6%	-46.5%	-41.5%	-43.5%
May 7	Goldman Sachs	Maintains	Buy → Buy	—	$7.27	$5.70	-21.6%	-41.3%	-44.6%	-46.5%	-41.5%	-43.5%
May 7	Raymond James	Maintains	Outperform → Outperform	—	$7.27	$5.70	-21.6%	-41.3%	-44.6%	-46.5%	-41.5%	-43.5%
Apr 17	Goldman Sachs	Maintains	Buy → Buy	—	$7.91	$7.86	-0.6%	-3.4%	-6.4%	-6.1%	-7.8%	-6.8%
Apr 9	Guggenheim	Downgrade	Buy → Neutral	—	$7.73	$7.37	-4.7%	+9.3%	+2.8%	+3.5%	+4.5%	+3.6%
Apr 1	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$8.87	$8.91	+0.5%	-0.3%	-0.8%	-5.2%	-8.3%	-9.0%
Mar 12	Piper Sandler	Upgrade	Neutral → Overweight	—	$10.25	$10.90	+6.3%	+1.6%	-5.4%	-1.8%	-1.3%	-3.4%
Mar 4	Piper Sandler	Maintains	Neutral → Neutral	—	$10.39	$10.25	-1.3%	+0.3%	-0.5%	+1.3%	-2.0%	-7.6%
Mar 3	BofA Securities	Maintains	Underperform → Underperform	—	$10.73	$10.85	+1.1%	-3.2%	-2.9%	-3.6%	-2.0%	-5.1%
Feb 25	Raymond James	Maintains	Outperform → Outperform	—	$13.78	$10.32	-25.1%	-14.8%	-16.1%	-19.7%	-22.1%	-24.6%
Feb 25	UBS	Maintains	Neutral → Neutral	—	$13.78	$10.32	-25.1%	-14.8%	-16.1%	-19.7%	-22.1%	-24.6%
Jan 30	Piper Sandler	Maintains	Neutral → Neutral	—	$12.54	$12.60	+0.5%	+3.0%	+1.0%	+1.8%	-1.0%	+3.1%
Jan 28	Goldman Sachs	Maintains	Buy → Buy	—	$12.96	$12.91	-0.4%	-3.5%	-3.2%	-0.4%	-2.2%	-1.5%
Jan 16	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$13.15	$13.15	+0.0%	-4.8%	-5.8%	-4.4%	-6.6%	-3.0%
Dec 13	BofA Securities	Maintains	Underperform → Underperform	—	$14.50	$14.34	-1.1%	-0.5%	-2.6%	-4.7%	-8.6%	-9.2%
Dec 9	Leerink Partners	Downgrade	Outperform → Market Perform	—	$15.13	$14.85	-1.9%	-1.7%	+1.4%	-4.1%	-4.2%	-4.6%
Nov 18	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$15.25	$15.05	-1.3%	-0.2%	-1.6%	+0.3%	-0.9%	+1.6%
Nov 11	Piper Sandler	Maintains	Neutral → Neutral	—	$17.41	$17.33	-0.5%	-0.6%	-7.1%	-9.4%	-9.9%	-12.4%
Aug 13	Piper Sandler	Maintains	Neutral → Neutral	—	$27.95	$28.29	+1.2%	+0.8%	-1.2%	-0.4%	+0.8%	+1.1%
Aug 13	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$27.95	$28.29	+1.2%	+0.8%	-1.2%	-0.4%	+0.8%	+1.1%
Aug 7	JP Morgan	Maintains	Underweight → Underweight	—	$25.96	$28.55	+10.0%	+2.6%	+6.6%	+7.7%	+7.7%	+8.6%
Aug 7	TD Cowen	Maintains	Hold → Hold	—	$25.96	$28.55	+10.0%	+2.6%	+6.6%	+7.7%	+7.7%	+8.6%
May 13	Piper Sandler	Maintains	Neutral → Neutral	—	$25.47	$25.48	+0.0%	-2.1%	-0.4%	-3.2%	-3.4%	-0.7%
May 8	Leerink Partners	Upgrade	Market Perform → Outperform	—	$19.78	$23.45	+18.6%	+21.1%	+27.7%	+28.8%	+26.0%	+28.2%
Jan 30	Goldman Sachs	Maintains	Buy → Buy	—	$22.72	$22.72	+0.0%	-0.9%	-5.9%	-4.9%	-6.4%	-3.8%
Jan 29	Goldman Sachs	Maintains	Buy → Buy	—	$22.22	$22.37	+0.7%	+2.3%	+1.3%	-3.7%	-2.7%	-4.3%
Nov 7	JP Morgan	Maintains	Underweight → Underweight	—	$16.34	$17.12	+4.8%	+8.7%	+9.5%	-0.3%	+0.7%	+0.9%
Aug 7	JP Morgan	Maintains	Underweight → Underweight	—	$19.31	$19.18	-0.7%	-9.5%	-11.7%	-12.3%	-13.6%	-7.4%
Jul 24	Goldman Sachs	Maintains	Buy → Buy	—	$23.08	$23.00	-0.3%	-4.6%	-4.0%	-4.3%	-5.8%	-2.8%
Jul 21	Goldman Sachs	Maintains	Buy → Buy	—	$22.18	$22.59	+1.8%	+4.1%	-0.7%	-0.1%	-0.4%	-1.9%
May 24	Goldman Sachs	Maintains	Buy → Buy	—	$22.68	$22.64	-0.2%	+1.1%	-2.5%	-1.7%	-1.9%	-2.7%
May 23	Goldman Sachs	Upgrade	Sell → Buy	—	$20.07	$21.97	+9.5%	+13.0%	+14.3%	+10.2%	+11.1%	+10.9%
May 4	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$21.89	$19.15	-12.5%	-3.7%	-11.9%	-16.3%	-17.8%	-18.8%
May 4	Goldman Sachs	Maintains	Sell → Sell	—	$21.89	$19.15	-12.5%	-3.7%	-11.9%	-16.3%	-17.8%	-18.8%
Mar 6	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$23.26	$23.41	+0.6%	-5.0%	-6.7%	-6.1%	-7.2%	-8.7%
Mar 3	Raymond James	Maintains	Outperform → Outperform	—	$22.90	$23.30	+1.7%	+1.6%	-3.5%	-5.2%	-4.6%	-5.7%
Jan 18	Raymond James	Upgrade	Market Perform → Outperform	—	$18.56	$19.90	+7.2%	+5.9%	+5.1%	+9.6%	+15.4%	+13.0%
Nov 2	SVB Leerink	Maintains	Market Perform → Market Perform	—	$17.50	$17.31	-1.1%	-6.9%	-9.8%	-5.5%	-6.9%	+2.9%
Oct 6	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$20.82	$20.62	-1.0%	-2.0%	-5.8%	-8.9%	-10.6%	-9.1%
Aug 5	SVB Leerink	Maintains	Market Perform → Market Perform	—	$27.40	$27.08	-1.2%	+0.2%	-1.0%	-4.4%	+0.3%	-2.6%
May 5	SVB Leerink	Maintains	Market Perform → Market Perform	—	$21.85	$21.00	-3.9%	-1.1%	-1.6%	-9.9%	-9.1%	-9.2%

Recent Filings

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

Leadership transitions with equity incentives can signal confidence in succession planning, but investors should monitor whether new executives meet performance targets to ensure shareholder value isn't diluted through excessive equity grants.

Mar 16

8-K

Myriad Genetics Inc -- 8-K Filing

Myriad Genetics disclosed financial information in an 8-K filing with limited liability protection, indicating the company provided guidance or results that won't be incorporated into future securities filings unless explicitly referenced.

Feb 23

Data updated apr 26, 2026 2:02pm · Source: massive.com